Wright Medical Group NV (Wright Medical Group NV) ROCE % : 1.46% (As of Sep. 2020)

View and export this data going back to 2011. Start your Free Trial

What is Wright Medical Group NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Wright Medical Group NV's annualized ROCE % for the quarter that ended in Sep. 2020 was 1.46%.

Wright Medical Group NV ROCE % Historical Data

The historical data trend for Wright Medical Group NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wright Medical Group NV ROCE % Chart

Wright Medical Group NV Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

ROCE %

Get a 7-Day Free Trial

-15.54

-6.51

-1.43

-4.55

0.08

Wright Medical Group NV Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
ROCE %	Get a 7-Day Free Trial															-2.71	3.79	2.56	-7.45	1.46

Wright Medical Group NV ROCE % Calculation

Wright Medical Group NV's annualized ROCE % for the fiscal year that ended in Dec. 2019 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2019 )		(A: Dec. 2018 )		(A: Dec. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2019 )		(A: Dec. 2018 )		(A: Dec. 2019 )
	=	1.683	/	( ( (2694.401 - 467.126)	+	(2585.64 - 850.008) )	/ 2 )
	=	1.683	/	( (2227.275	+	1735.632)	/ 2 )
	=	1.683	/	1981.4535
	=	0.08 %

Wright Medical Group NV's ROCE % of for the quarter that ended in Sep. 2020 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2020 )		(Q: Jun. 2020 )		(Q: Sep. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2020 )		(Q: Jun. 2020 )		(Q: Sep. 2020 )
	=	24.784	/	( ( (2563.527 - 861.215)	+	(2598.719 - 907.803) )	/ 2 )
	=	24.784	/	( ( 1702.312	+	1690.916 )	/ 2 )
	=	24.784	/	1696.614
	=	1.46 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

Wright Medical Group NV (NAS:WMGI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Wright Medical Group NV ROCE % Related Terms

Thank you for viewing the detailed overview of Wright Medical Group NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Wright Medical Group NV (Wright Medical Group NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wright Medical Group NV (NAS:WMGI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prins Bernhardplein 200, Amsterdam, NLD, 1097 JB

Website

http://www.wright.com

Wright Medical Group develops medical devices and products in five categories: lower extremities, upper extremities, biologics, large joints, and sports medicine, and other. Products for lower extremities include joint implants and bone fixation devices for the foot and ankle, whereas products for upper extremities include implants and devices for the shoulder, elbow, wrist, and hand. The biologics business sells products used to treat damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. The large joints business sells hip and knee replacement implants. The firm's sports medicine products are used to mechanically repair tissue injuries. Wright Medical Group generates the majority of its revenue in the United States.

Executives

Steven P. Wallace	officer: President, International	1023 CHERRY ROAD MEMPHIS TN 38117
Barry J. Regan	officer: SVP, Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Kevin C. Smith	officer: SVP, Quality and Regulatory	1023 CHERRY ROAD MEMPHIS TN 38117
Jason D. Asper	officer: SVP, Chief Digital Officer	1023 CHERRY ROAD MEMPHIS TN 38117
Tim Lanier	officer: President, Upper Extremities	1023 CHERRY ROAD MEMPHIS TN 38117
Patrick Fisher	officer: President, Lower Extremities	1023 CHERRY ROAD MEMPHIS TN 38117
Jonathan Wesley Porter	officer: SVP, Chief Compliance Officer	1023 CHERRY ROAD MEMPHIS TN 38117
Julie Andrews	officer: SVP, Global Finance	5677 AIRLINE ROAD, ARLINGTON TN 38002
Jennifer S. Walker	officer: SVP, Process Improvement	5677 AIRLINE ROAD ARLINGTON TN 38002
Andrew C. Morton	officer: SVP, Chief Human Resources Ofr	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Lance A Berry	officer: EVP, Chief Finan./Op. Officer	5677 AIRLINE ROAD, ARLINGTON TN 38002
Julie D. Dewey	officer: SVP, Chief Comm. Officer	1023 CHERRY ROAD MEMPHIS TN 38117
Kevin D Cordell	officer: EVP, Chief Global Comm Officer	C/O WRIGHT MEDICAL GROUP, INC. 1023 CHERRY ROAD MEMPHIS TN 38117
Robert J Palmisano	director, officer: President and Chief Executive	110 HARTWELL AVENUE, LEXINGTON MA 02173
Peter Cooke	officer: Pres. Emerging Markets AUS/JAP	5677 AIRLINE ROAD ARLINGTON TN 38002